Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Hand-Foot Syndrome 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Fluorouracil 70Leucovorin 66Oxaliplatin 50Irinotecan 32Cetuximab 23Bevacizumab 20Capecitabine 16Chemotherapy, Adjuvant 15Folfox protocol 13sargramostim 7Neoadjuvant Therapy 7Erlotinib Hydrochloride 7aldesleukin 5Trastuzumab 5Melphalan 5Magnetic Resonance Spectroscopy 5Gene Expression Profiling 5Floxuridine 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5dehydroftorafur 4Specimen Handling 4Polymerase Chain Reaction 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Gefitinib 4Disulfides 4Cyclophosphamide 4fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colonic Neoplasms × Pyridoxine × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡